Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Jason Clapper

Physician Assistant Moorestown, NJ Physician Assistant

NPI 1487386280 CMS profile 11374206

300 W Route 38 Ste A, Moorestown, NJ 08057

Open in the dashboard

General payments

$3,880

59 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jason Clapper of Moorestown, NJ is reported in the CMS Open Payments database as having received $3,880 across 59 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $546 10
2024 General $1,540 25
2023 General $408 5
2022 General $1,386 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Clapper
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jason Clapper were reported at $546. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jason Clapper Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $1,386 $155 $48–$522 $149
2023 $408 $167 $52–$557 $160
2024 $1,540 $178 $55–$600 $164
2025 $546 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Stryker Corporation $1,769 28 payments
  2. Eclipse Technology Solutions Inc. $905 6 payments
  3. Arthrex, Inc. $642 15 payments
  4. Zimmer Biomet Holdings, Inc. $218 2 payments
  5. Davol Inc. $159 1 payment
  6. Boston Scientific Corporation $93 3 payments
  7. SI-BONE, Inc. $36 1 payment
  8. ConvaTec Inc. $24 1 payment
  9. Ossur Americas., Inc $20 1 payment
  10. AbbVie, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $2,859 56 payments
  2. Travel and Lodging $1,021 3 payments
Products named General payments · program years 2022–2025
  1. MAKO $1,417 19 payments
  2. TRIATHLON $1,138 16 payments
  3. INSIGNIA $814 13 payments
  4. TRIDENT $579 8 payments
  5. RESTORATION $536 11 payments
  6. Persona $218 2 payments
  7. ACCOLADE $172 2 payments
  8. ARISTA AH FlexiTip $159 1 payment
  9. X3 $114 1 payment
  10. OMNIFIT $114 1 payment
  11. Other $243 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

516

Median for Physician Assistant: 241

Drug cost

$2,920

Median for Physician Assistant: $4,110

Branded share of claims

15.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Er Diclofenac Sodium Brand 26 $488
Celecoxib Generic 24 $446
Pregabalin Generic 43 $320
Doxycycline Hyclate Generic 40 $307
Oxycodone Hcl Generic 79 $285
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 41 $271
Cefadroxil Generic 20 $171
Methylprednisolone Generic 30 $170
Meloxicam Generic 65 $131
Famotidine Generic 54 $98

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$77,947

Of which drugs: $31,085

Medicare patients

284

Average age 75

Services billed

953

174 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 32%
Ischemic heart disease 27%
Chronic kidney disease 23%
Atrial fibrillation 21%
Depression 21%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 Office 36 57 $30,168
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 69 179 $128

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

59 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record